Latest Breaking News On - Multiple myeloma - Page 15 : vimarsana.com

U S Gene Therapy Market Size, Share & Trends Analysis

Dublin, April 23, 2024 (GLOBE NEWSWIRE) The

United statesVertex pharmaceuticals incorporatedCompany market position analysisRoute of administrationSarepta therapeutics incKrystal biotech incRoute of administration business analysisAmgen incMerck coBristol myers squibb companyPorter five forces analysisCompany categorizationRoute of administration segment dashboardCompany profiles listingGilead sciences incTherapy market size

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy Expanded indication for this one-time infusion may provide pati.

Region flamandeEdmond chanDrug administrationEuropean unionCommittee for orphan medicinal productsJanssen cilag internationalEuropean medicines agencyEuropean commissionArea lead haematologyJohnson innovativeNew england journalProfessor jesSan miguelTranslational medicineUniversidad de navarraJordan schecter

Study points to racial and social barriers that block treatment for multiple myeloma

Study points to racial and social barriers that block treatment for multiple myeloma
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United statesTheresa keeganNaseems esteghamatNaseem esteghamatA uc davis healthMarrow transplant researchInternational bloodUc davis comprehensive cancer centerClinical lymphomaCalifornia cancer registryCalifornia patient dischargeAfrican americanMultiple myelomaPopulation based study

Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy

Media contact: Investor contact: .

United statesRegion flamandeEdmond chanJenni mildonCiltacabtagene autoleucelEuropean commission grants conditional approvalLegend biotech united states incJanssen biotech incDrug administrationAmerican society of clinical oncologyEuropean commissionJanssen cilag internationalChinese company legend biotech to develop investigationalAmerican cancer societyCommittee for orphan medicinal productsJanssen research development

European Commission Approves Cilta-Cel for Relapsed/Refractory Multiple Myeloma

Cilta-cel has received approval from the European Commission for multiple myeloma that is relapsed or refractory to at least 1 prior line of therapy.

Edmond chanJohnson companyEuropean commissionTherapeutic area lead for haematology at janssen cilagSan miguelTranslational medicineUniversidad de navarraArea leadJanssen cilag limitedMultiple myelomaJohnson innovative medicineCilta celJesús san miguelMultiple myeloma that is relapsed or refractory